All News
Kevzara (Sarilumab) Approved in Canada for RA
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
Read ArticleIs the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Read ArticleCurbside Consults - January 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Read ArticleThe RheumNow Week in Review – 27 January 2017
Dr. Cush reviews highlights from the past week on RheumNow.com.
Read ArticleDSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read ArticleFDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read ArticleThe RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read ArticleConsensus Guidelines for Juvenile Dermatomyositis Management
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Read ArticleRituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read ArticleThe RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read ArticleTREG Innovators Win the Crafoord Prize
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Read ArticleLess Education Yields Higher Cardiovascular Risk
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Read ArticleThe RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read ArticlePregnancy Outcomes in Psoriatic Arthritis
Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2
DMARDs Under Study for Secondary Prevention of Cardiovascular Events
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Read ArticleA Low Risk of Inflammatory Bowel Disease with IL-17 Inhibition
Colitis onset or worsening inflammatory bowel disease has been reported with either of the new IL-17 inhibitors, ixekizumab (IXE) and secukinumab (SEC). Large database studies show these to be rare.
Read ArticleCHMP Recommend Baricitinib for Approval in Europe
Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R
Read ArticleA Link Between Periodontal Disease and Rheumatoid Arthritis
Research from Johns Hopkins reports that rheumatoid arthritis (RA) patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to that seen in RA. Results published in Science Translational Medicine showed that Aggregatibacter actinomycetemcomitans can produce hypercitrullination of patient neutrophils, indicating its possible role in triggering RA. (Citation source: http://buff.ly/2hZTBG8)
Read ArticleRheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Read Article